Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 2,572 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,572 shares of the firm’s stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $153,677.00. Following the sale, the insider now directly owns 163,309 shares in the company, valued at approximately $9,757,712.75. The trade was a 1.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Monday, June 16th, Soleil Boughton sold 5,451 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.80, for a total value of $309,616.80.
• On Tuesday, May 27th, Soleil Boughton sold 3,233 shares of Hims & Hers Health stock. The shares were sold at an average price of $55.87, for a total value of $180,627.71.
• On Monday, April 28th, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.19, for a total value of $97,694.84.
• On Monday, April 14th, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.72, for a total value of $92,937.92.
• On Monday, March 31st, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.77, for a total value of $89,863.72.

Hims & Hers Health Stock Down 1.0%

Shares of NYSE:HIMS opened at $59.17 on Wednesday. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98. The stock has a market cap of $13.24 billion, a price-to-earnings ratio of 85.75, a PEG ratio of 2.25 and a beta of 2.09. The business has a 50-day moving average price of $46.36 and a 200-day moving average price of $38.60.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. Hims & Hers Health’s revenue for the quarter was up 110.7% compared to the same quarter last year. During the same period last year, the company earned $0.05 earnings per share. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on HIMS shares. TD Cowen cut Hims & Hers Health from a “buy” rating to a “hold” rating and decreased their price target for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Needham & Company LLC increased their price target on Hims & Hers Health from $61.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, June 4th. Wall Street Zen upgraded Hims & Hers Health from a “hold” rating to a “buy” rating in a research note on Sunday. Citigroup restated a “sell” rating and issued a $30.00 price objective (up from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, Bank of America raised their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the stock an “underperform” rating in a research note on Tuesday, April 29th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average target price of $38.00.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geneos Wealth Management Inc. acquired a new stake in Hims & Hers Health during the first quarter worth about $30,000. Blume Capital Management Inc. grew its holdings in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 600 shares during the period. UMB Bank n.a. grew its holdings in Hims & Hers Health by 247.5% during the first quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock worth $39,000 after acquiring an additional 933 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Hims & Hers Health during the first quarter worth about $41,000. Finally, Larson Financial Group LLC grew its holdings in Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after acquiring an additional 458 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.